AMF Tjanstepension AB Has $1.17 Million Stock Position in Zoetis Inc. $ZTS

Key Points

• AMF Tjanstepension AB significantly reduced its stake in Zoetis Inc. (NYSE:ZTS) by 91.9%, decreasing its holdings to 7,481 shares worth approximately $1.17 million after selling 85,375 shares during the second quarter.
• Zoetis recently reported quarterly earnings of $1.76 per share, surpassing analysts' expectations, with revenue of $2.46 billion, reflecting a 4.2% increase compared to the previous year.
• Research analysts have mixed opinions on Zoetis stock, with a consensus rating of "Moderate Buy" and an average price target set at $200.88, indicating potential for growth.

AMF Tjanstepension AB lowered its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 91.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,481 shares of the company's stock after selling 85,375 shares during the period. AMF Tjanstepension AB's holdings in Zoetis were worth $1,167,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Sound Income Strategies LLC boosted its stake in Zoetis by 54.3% during the second quarter. Sound Income Strategies LLC now owns 432 shares of the company's stock worth $67,000 after buying an additional 152 shares in the last quarter. Portside Wealth Group LLC boosted its stake in Zoetis by 24.7% during the first quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock worth $5,550,000 after buying an additional 6,672 shares in the last quarter. Tandem Investment Advisors Inc. boosted its stake in Zoetis by 100.3% during the first quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock worth $65,140,000 after buying an additional 198,089 shares in the last quarter. Soros Capital Management LLC boosted its stake in Zoetis by 32.0% during the first quarter. Soros Capital Management LLC now owns 17,441 shares of the company's stock worth $2,872,000 after buying an additional 4,230 shares in the last quarter. Finally, Flagship Harbor Advisors LLC boosted its stake in Zoetis by 31.2% during the first quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock worth $1,217,000 after buying an additional 1,760 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Performance

Zoetis stock opened at $146.45 on Friday. The stock has a 50-day simple moving average of $149.79 and a 200 day simple moving average of $155.08. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12-month low of $139.34 and a 12-month high of $196.55. The stock has a market capitalization of $64.91 billion, a price-to-earnings ratio of 25.21, a P/E/G ratio of 2.35 and a beta of 0.90.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. During the same period in the previous year, the business posted $1.56 earnings per share. The firm's revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on ZTS. Weiss Ratings reiterated a "hold (c-)" rating on shares of Zoetis in a research note on Saturday, September 27th. Argus restated a "buy" rating and issued a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and reduced their target price for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Piper Sandler boosted their target price on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Five equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.